# The Misuse of Drugs (Amendment No. 2) Regulations (Northern Ireland) 2020

S.R. 2020/104 · made 12 June 2020

These Regulations amend the Misuse of Drugs Regulations (Northern Ireland) 2002 (S.R. 2002 No. 1) to provide for a specified cannabis-based medicine to be placed in Schedule 5 of the Regulations. The effect of this is that the specified product is exempt from the prohibitions on import, export and possession under sections 3 and 5 of the Misuse of Drugs Act 1971.

Made under: Misuse of Drugs Act 1971 (Section 7, Section 10, Section 22, Section 31, Section 38)

PDFs: Printed copy https://openlegislation.uk/misuse-of-drugs-amendment-no-2-regulations-northern-ireland-2020/pdf/nisr_20200104_en.pdf; NI Explanatory Memorandum https://openlegislation.uk/misuse-of-drugs-amendment-no-2-regulations-northern-ireland-2020/pdf/nisrem_20200104_en.pdf

## Introductory text

Dangerous Drugs
Made 12th June 2020
Coming into operation 24th June 2020
The Department of Health makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971 as adapted by sections 7(9), 31(4) and 38 of that Act and now vested in it and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 31(3) of that Act.

## 1 Citation, commencement and interpretation

(1) These Regulations may be cited as the Misuse of Drugs (Amendment No. 2) Regulations (Northern Ireland) 2020 and shall come into operation on 24th June 2020.
(2) The Interpretation Act (Northern Ireland) 1954 shall apply to these Regulations as it applies to an Act of the Northern Ireland Assembly.

## 2 Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002

The Misuse of Drugs Regulations (Northern Ireland) 2002 are amended as follows.
(1) In regulation 2 (2) (interpretation), in the definition of “cannabis-based product for medicinal use in humans”, for “Schedule 4 applies” substitute—
“Schedule 4, or paragraph 10 of Schedule 5, applies”.
(2) In paragraph 1(a) of Schedule 1 (controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27), for “Cannabinol derivatives not being dronabinol or its stereoisomers” substitute—
“Cannabinol derivatives not being—
(i) dronabinol or its stereoisomers; or
(ii) the substance specified in paragraph 10 of Schedule 5.”
(3) In Schedule 5 (controlled drugs excepted from the prohibition on importation, exportation and possession and subject to the requirements of regulations 24 and 26), after paragraph 9 insert—
“10. A liquid formulation—
(a) containing cannabidiol obtained by extraction and purification from cannabis;
(b) where the concentration of—
(i) delta-9-tetrahydrocannabinol is not more than 0.1 milligram per millilitre; and
(ii) cannabidiol is 95-105 milligrams per millilitre;
(c) which is presented in a bottle, as an oral solution for oral administration; and
(d) which was approved for marketing by the European Commission on 19th September 2019.”.

## Signature

Sealed with the Official Seal of the Department of Health on 12th June 2020.
(L.S.)
Cathy Harrison
A senior officer of the Department of Health

## Explanatory note

(This note is not part of the Regulations)
These Regulations amend the Misuse of Drugs Regulations (Northern Ireland) 2002 (S.R. 2002 No. 1) to provide for a specified cannabis-based medicine to be placed in Schedule 5 of the Regulations. The effect of this is that the specified product is exempt from the prohibitions on import, export and possession under sections 3 and 5 of the Misuse of Drugs Act 1971.

---
Source: https://www.legislation.gov.uk/nisr/2020/104 (the official version)
Page: https://openlegislation.uk/misuse-of-drugs-amendment-no-2-regulations-northern-ireland-2020
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.